Jasper Therapeutics, Inc. (NASDAQ: JSPRW) Stock Competitors & Peer Comparison
See JSPRW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for JSPRW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| JSPRW | $0.00 | -84.62% | 3.3K | N/A | -$1.59 | N/A |
| VRTX | $527.67 | +0.28% | 133.9B | 27.73 | $19.03 | N/A |
| MRNA | $197.28 | -0.80% | 78.3B | -24.21 | -$8.15 | N/A |
| REGN | $752.25 | -4.54% | 77.5B | 16.49 | $45.63 | +0.49% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $972.25 | +1.33% | 60.5B | 35.06 | $27.73 | N/A |
| RVMDW | $11.22 | -3.48% | 44B | -1.27 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $201.74 | -1.58% | 42.9B | -22.87 | -$8.82 | N/A |
| ONC | $367.00 | +1.70% | 39.2B | 64.61 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
JSPRW vs VRTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, VRTX has a market cap of 133.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while VRTX trades at $527.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 27.73. In terms of profitability, JSPRW's ROE is -6.19%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, JSPRW is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
JSPRW vs MRNA Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, MRNA has a market cap of 78.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while MRNA trades at $197.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -24.21. In terms of profitability, JSPRW's ROE is -6.19%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, JSPRW is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
JSPRW vs REGN Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, REGN has a market cap of 77.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while REGN trades at $752.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 16.49. In terms of profitability, JSPRW's ROE is -6.19%, compared to REGN's ROE of +0.14%. Regarding short-term risk, JSPRW is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
JSPRW vs VRNA Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, JSPRW's ROE is -6.19%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, JSPRW is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
JSPRW vs ARGX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ARGX has a market cap of 60.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ARGX trades at $972.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 35.06. In terms of profitability, JSPRW's ROE is -6.19%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, JSPRW is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
JSPRW vs RVMDW Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, RVMDW has a market cap of 44B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while RVMDW trades at $11.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas RVMDW's P/E ratio is -1.27. In terms of profitability, JSPRW's ROE is -6.19%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, JSPRW is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check RVMDW's competition here
Seagen Inc. (NASDAQ: SGEN)
JSPRW vs SGEN Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, JSPRW's ROE is -6.19%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, JSPRW is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
JSPRW vs RVMD Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, RVMD has a market cap of 42.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while RVMD trades at $201.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -22.87. In terms of profitability, JSPRW's ROE is -6.19%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, JSPRW is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
JSPRW vs ONC Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ONC has a market cap of 39.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ONC trades at $367.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ONC's P/E ratio is 64.61. In terms of profitability, JSPRW's ROE is -6.19%, compared to ONC's ROE of +0.14%. Regarding short-term risk, JSPRW is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
JSPRW vs ALNY Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ALNY has a market cap of 34.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ALNY trades at $255.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 46.01. In terms of profitability, JSPRW's ROE is -6.19%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, JSPRW is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
JSPRW vs ROIV Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ROIV has a market cap of 26.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ROIV trades at $36.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -35.18. In terms of profitability, JSPRW's ROE is -6.19%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, JSPRW is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
JSPRW vs INSM Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, INSM has a market cap of 25.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while INSM trades at $117.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -28.63. In terms of profitability, JSPRW's ROE is -6.19%, compared to INSM's ROE of -1.11%. Regarding short-term risk, JSPRW is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
JSPRW vs INCY Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, INCY has a market cap of 25.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while INCY trades at $124.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 16.78. In terms of profitability, JSPRW's ROE is -6.19%, compared to INCY's ROE of +0.30%. Regarding short-term risk, JSPRW is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
JSPRW vs BNTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, BNTX has a market cap of 24.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while BNTX trades at $99.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -12.85. In terms of profitability, JSPRW's ROE is -6.19%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, JSPRW is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
JSPRW vs GMAB Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, GMAB has a market cap of 21.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while GMAB trades at $35.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 26.65. In terms of profitability, JSPRW's ROE is -6.19%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, JSPRW is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
JSPRW vs UTHR Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, UTHR has a market cap of 20.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while UTHR trades at $485.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 17.37. In terms of profitability, JSPRW's ROE is -6.19%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, JSPRW is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
JSPRW vs BGNE Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, JSPRW's ROE is -6.19%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, JSPRW is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
JSPRW vs DNA-WT Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, JSPRW's ROE is -6.19%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, JSPRW is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
JSPRW vs JAZZ Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while JAZZ trades at $238.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 8.88. In terms of profitability, JSPRW's ROE is -6.19%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, JSPRW is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
JSPRW vs EXEL Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while EXEL trades at $58.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 16.68. In terms of profitability, JSPRW's ROE is -6.19%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, JSPRW is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
JSPRW vs ASND Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ASND has a market cap of 14.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ASND trades at $230.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -95.06. In terms of profitability, JSPRW's ROE is -6.19%, compared to ASND's ROE of +1.90%. Regarding short-term risk, JSPRW is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
JSPRW vs NBIX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, NBIX has a market cap of 14.1B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while NBIX trades at $140.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 20.29. In terms of profitability, JSPRW's ROE is -6.19%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, JSPRW is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check NBIX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
JSPRW vs HALO Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, HALO has a market cap of 13.4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while HALO trades at $112.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 21.06. In terms of profitability, JSPRW's ROE is -6.19%, compared to HALO's ROE of +1.81%. Regarding short-term risk, JSPRW is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
JSPRW vs BBIO Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while BBIO trades at $66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -17.81. In terms of profitability, JSPRW's ROE is -6.19%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, JSPRW is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
JSPRW vs KRTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, JSPRW's ROE is -6.19%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, JSPRW is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check KRTX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
JSPRW vs SMMT Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, SMMT has a market cap of 12.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while SMMT trades at $15.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -13.82. In terms of profitability, JSPRW's ROE is -6.19%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, JSPRW is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check SMMT's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
JSPRW vs MDGL Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while MDGL trades at $517.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -40.39. In terms of profitability, JSPRW's ROE is -6.19%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, JSPRW is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check MDGL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
JSPRW vs BMRN Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while BMRN trades at $59.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 28.59. In terms of profitability, JSPRW's ROE is -6.19%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, JSPRW is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
JSPRW vs TECH Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while TECH trades at $72.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 37.38. In terms of profitability, JSPRW's ROE is -6.19%, compared to TECH's ROE of +0.09%. Regarding short-term risk, JSPRW is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
JSPRW vs RNAM Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, JSPRW's ROE is -6.19%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, JSPRW is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check RNAM's competition here
10x Genomics, Inc. (NASDAQ: TXG)
JSPRW vs TXG Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, TXG has a market cap of 11.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while TXG trades at $88.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -150.00. In terms of profitability, JSPRW's ROE is -6.19%, compared to TXG's ROE of -0.09%. Regarding short-term risk, JSPRW is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
JSPRW vs TWST Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, TWST has a market cap of 11.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while TWST trades at $179.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas TWST's P/E ratio is -80.90. In terms of profitability, JSPRW's ROE is -6.19%, compared to TWST's ROE of -0.30%. Regarding short-term risk, JSPRW is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check TWST's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
JSPRW vs AXSM Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, AXSM has a market cap of 10B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while AXSM trades at $193.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -50.62. In terms of profitability, JSPRW's ROE is -6.19%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, JSPRW is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
JSPRW vs KRYS Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while KRYS trades at $337.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 42.24. In terms of profitability, JSPRW's ROE is -6.19%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, JSPRW is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
JSPRW vs RXDX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, JSPRW's ROE is -6.19%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, JSPRW is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check RXDX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
JSPRW vs ARWR Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ARWR has a market cap of 9.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ARWR trades at $65.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -29.09. In terms of profitability, JSPRW's ROE is -6.19%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, JSPRW is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ARWR's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
JSPRW vs KYMR Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while KYMR trades at $112.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -35.00. In terms of profitability, JSPRW's ROE is -6.19%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, JSPRW is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
JSPRW vs PTGX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while PTGX trades at $142.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 138.29. In terms of profitability, JSPRW's ROE is -6.19%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, JSPRW is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
JSPRW vs NUVL Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -21.79. In terms of profitability, JSPRW's ROE is -6.19%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, JSPRW is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
JSPRW vs CRNX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -16.86. In terms of profitability, JSPRW's ROE is -6.19%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, JSPRW is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CRNX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
JSPRW vs CAI Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CAI has a market cap of 9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CAI trades at $31.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CAI's P/E ratio is 89.21. In terms of profitability, JSPRW's ROE is -6.19%, compared to CAI's ROE of +0.19%. Regarding short-term risk, JSPRW is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CAI's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
JSPRW vs IBRX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while IBRX trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -8.78. In terms of profitability, JSPRW's ROE is -6.19%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, JSPRW is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check IBRX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
JSPRW vs IMGN Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, JSPRW's ROE is -6.19%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, JSPRW is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
JSPRW vs TGTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while TGTX trades at $56.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 20.36. In terms of profitability, JSPRW's ROE is -6.19%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, JSPRW is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check TGTX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
JSPRW vs PCVX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while PCVX trades at $58.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -7.64. In terms of profitability, JSPRW's ROE is -6.19%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, JSPRW is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
JSPRW vs BPMC Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, JSPRW's ROE is -6.19%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, JSPRW is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
JSPRW vs APGE Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -31.19. In terms of profitability, JSPRW's ROE is -6.19%, compared to APGE's ROE of -0.30%. Regarding short-term risk, JSPRW is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check APGE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
JSPRW vs CYTK Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CYTK trades at $66.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -9.16. In terms of profitability, JSPRW's ROE is -6.19%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, JSPRW is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CYTK's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
JSPRW vs CERE Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, JSPRW's ROE is -6.19%, compared to CERE's ROE of -0.72%. Regarding short-term risk, JSPRW is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CERE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
JSPRW vs PRAX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, PRAX has a market cap of 8B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while PRAX trades at $285.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -22.09. In terms of profitability, JSPRW's ROE is -6.19%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, JSPRW is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check PRAX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
JSPRW vs IONS Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, IONS has a market cap of 7.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while IONS trades at $45.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -13.94. In terms of profitability, JSPRW's ROE is -6.19%, compared to IONS's ROE of -1.11%. Regarding short-term risk, JSPRW is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check IONS's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
JSPRW vs SYRE Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, SYRE has a market cap of 7.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while SYRE trades at $85.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -43.99. In terms of profitability, JSPRW's ROE is -6.19%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, JSPRW is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
JSPRW vs MTSR Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, JSPRW's ROE is -6.19%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, JSPRW is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check MTSR's competition here
Abivax S.A. (NASDAQ: ABVX)
JSPRW vs ABVX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ABVX has a market cap of 7.1B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ABVX trades at $96.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -18.43. In terms of profitability, JSPRW's ROE is -6.19%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, JSPRW is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
JSPRW vs IMVT Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while IMVT trades at $33.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -11.88. In terms of profitability, JSPRW's ROE is -6.19%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, JSPRW is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check IMVT's competition here
Merus N.V. (NASDAQ: MRUS)
JSPRW vs MRUS Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, JSPRW's ROE is -6.19%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, JSPRW is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
JSPRW vs RYTM Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while RYTM trades at $98.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -31.69. In terms of profitability, JSPRW's ROE is -6.19%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, JSPRW is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
JSPRW vs ACLX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.27. In terms of profitability, JSPRW's ROE is -6.19%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, JSPRW is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ACLX's competition here
Belite Bio, Inc (NASDAQ: BLTE)
JSPRW vs BLTE Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while BLTE trades at $165.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -88.73. In terms of profitability, JSPRW's ROE is -6.19%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, JSPRW is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check BLTE's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
JSPRW vs RETA Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, JSPRW's ROE is -6.19%, compared to RETA's ROE of +0.47%. Regarding short-term risk, JSPRW is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check RETA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
JSPRW vs LGND Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while LGND trades at $314.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 34.48. In terms of profitability, JSPRW's ROE is -6.19%, compared to LGND's ROE of +0.20%. Regarding short-term risk, JSPRW is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check LGND's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
JSPRW vs CNTA Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -22.63. In terms of profitability, JSPRW's ROE is -6.19%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, JSPRW is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CNTA's competition here
CG Oncology Inc. (NASDAQ: CGON)
JSPRW vs CGON Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CGON trades at $69.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -25.88. In terms of profitability, JSPRW's ROE is -6.19%, compared to CGON's ROE of -0.25%. Regarding short-term risk, JSPRW is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CGON's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
JSPRW vs SRRK Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while SRRK trades at $49.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -14.24. In terms of profitability, JSPRW's ROE is -6.19%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, JSPRW is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check SRRK's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
JSPRW vs TVTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, TVTX has a market cap of 5.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while TVTX trades at $61.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -136.82. In terms of profitability, JSPRW's ROE is -6.19%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, JSPRW is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check TVTX's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
JSPRW vs KOD Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, KOD has a market cap of 5.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while KOD trades at $89.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas KOD's P/E ratio is -21.56. In terms of profitability, JSPRW's ROE is -6.19%, compared to KOD's ROE of -2.73%. Regarding short-term risk, JSPRW is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
JSPRW vs CDTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, JSPRW's ROE is -6.19%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, JSPRW is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
JSPRW vs ABCM Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, JSPRW's ROE is -6.19%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, JSPRW is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
JSPRW vs ISEE Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, JSPRW's ROE is -6.19%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, JSPRW is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
JSPRW vs PTCT Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while PTCT trades at $65.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is -28.30. In terms of profitability, JSPRW's ROE is -6.19%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, JSPRW is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check PTCT's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
JSPRW vs COGT Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while COGT trades at $31.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -15.10. In terms of profitability, JSPRW's ROE is -6.19%, compared to COGT's ROE of -0.73%. Regarding short-term risk, JSPRW is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check COGT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
JSPRW vs MIRM Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while MIRM trades at $87.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -6.05. In terms of profitability, JSPRW's ROE is -6.19%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, JSPRW is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check MIRM's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
JSPRW vs APLS Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 38.35. In terms of profitability, JSPRW's ROE is -6.19%, compared to APLS's ROE of +0.40%. Regarding short-term risk, JSPRW is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
JSPRW vs CRSP Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CRSP trades at $54.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -11.36. In terms of profitability, JSPRW's ROE is -6.19%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, JSPRW is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
JSPRW vs DFTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while DFTX trades at $38.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas DFTX's P/E ratio is N/A. In terms of profitability, JSPRW's ROE is -6.19%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, JSPRW is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check DFTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
JSPRW vs ORKA Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ORKA trades at $84.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ORKA's P/E ratio is -43.40. In terms of profitability, JSPRW's ROE is -6.19%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, JSPRW is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ORKA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
JSPRW vs DNTH Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while DNTH trades at $87.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -21.16. In terms of profitability, JSPRW's ROE is -6.19%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, JSPRW is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check DNTH's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
JSPRW vs IOVA Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, IOVA has a market cap of 4.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while IOVA trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas IOVA's P/E ratio is -15.05. In terms of profitability, JSPRW's ROE is -6.19%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, JSPRW is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check IOVA's competition here
Erasca, Inc. (NASDAQ: ERAS)
JSPRW vs ERAS Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ERAS has a market cap of 4.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ERAS trades at $14.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -15.19. In terms of profitability, JSPRW's ROE is -6.19%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, JSPRW is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
JSPRW vs MANE Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, MANE has a market cap of 4.8B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while MANE trades at $115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas MANE's P/E ratio is -36.56. In terms of profitability, JSPRW's ROE is -6.19%, compared to MANE's ROE of -0.38%. Regarding short-term risk, JSPRW is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check MANE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
JSPRW vs TERN Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.41. In terms of profitability, JSPRW's ROE is -6.19%, compared to TERN's ROE of -0.20%. Regarding short-term risk, JSPRW is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check TERN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
JSPRW vs ADPT Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ADPT trades at $28.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ADPT's P/E ratio is -69.54. In terms of profitability, JSPRW's ROE is -6.19%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, JSPRW is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
JSPRW vs FOLD Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -161.00. In terms of profitability, JSPRW's ROE is -6.19%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, JSPRW is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
JSPRW vs AKRO Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, JSPRW's ROE is -6.19%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, JSPRW is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
JSPRW vs ALPN Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, JSPRW's ROE is -6.19%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, JSPRW is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ALPN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
JSPRW vs EWTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while EWTX trades at $39.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -21.51. In terms of profitability, JSPRW's ROE is -6.19%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, JSPRW is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check EWTX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
JSPRW vs ABCL Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, ABCL has a market cap of 4.3B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while ABCL trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas ABCL's P/E ratio is -25.78. In terms of profitability, JSPRW's ROE is -6.19%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, JSPRW is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check ABCL's competition here
Opthea Limited (NASDAQ: OPT)
JSPRW vs OPT Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, JSPRW's ROE is -6.19%, compared to OPT's ROE of +1.18%. Regarding short-term risk, JSPRW is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
JSPRW vs PRTC Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas PRTC's P/E ratio is -3.78. In terms of profitability, JSPRW's ROE is -6.19%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, JSPRW is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
JSPRW vs MRTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, JSPRW's ROE is -6.19%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, JSPRW is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check MRTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
JSPRW vs TNGX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while TNGX trades at $24.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas TNGX's P/E ratio is -29.28. In terms of profitability, JSPRW's ROE is -6.19%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, JSPRW is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
JSPRW vs TLX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, TLX has a market cap of 3.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while TLX trades at $11.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 121.29. In terms of profitability, JSPRW's ROE is -6.19%, compared to TLX's ROE of +0.07%. Regarding short-term risk, JSPRW is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check TLX's competition here
Celcuity Inc. (NASDAQ: CELC)
JSPRW vs CELC Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CELC trades at $79.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -18.52. In terms of profitability, JSPRW's ROE is -6.19%, compared to CELC's ROE of -3.51%. Regarding short-term risk, JSPRW is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CELC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
JSPRW vs RLAY Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, RLAY has a market cap of 3.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while RLAY trades at $17.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas RLAY's P/E ratio is -11.27. In terms of profitability, JSPRW's ROE is -6.19%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, JSPRW is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check RLAY's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
JSPRW vs CPRX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 17.49. In terms of profitability, JSPRW's ROE is -6.19%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, JSPRW is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CPRX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
JSPRW vs VKTX Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while VKTX trades at $33.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -7.09. In terms of profitability, JSPRW's ROE is -6.19%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, JSPRW is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check VKTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
JSPRW vs PBLS Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, PBLS has a market cap of 3.8B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while PBLS trades at $32.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas PBLS's P/E ratio is -17.32. In terms of profitability, JSPRW's ROE is -6.19%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, JSPRW is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check PBLS's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
JSPRW vs RYZB Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, JSPRW's ROE is -6.19%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, JSPRW is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
JSPRW vs CBAY Comparison September 2026
Jasper Therapeutics, Inc. (NASDAQ: JSPRW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JSPRW stands at 3.3K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, JSPRW is priced at $0.00 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JSPRW currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, JSPRW's ROE is -6.19%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, JSPRW is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for JSPRW.Check CBAY's competition here